CERVICAL SQUAMOUS CELL CARCINOMA
Clinical trials for CERVICAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a triple therapy beat cervical cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental immunotherapy cocktail takes on tough tumors
Disease control OngoingThis early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC